(Q41378759)

English

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).

scientific article published on 25 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

1

object named as

Helio S Sader

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

3

object named as

Robert K Flamm

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

4

object named as

Ronald N Jones

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

author name string

David J Farrell

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

language of work or name

0 references

publication date

25 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

2053-2056

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Staphylococcus aureus bacteremia, risk factors, complications, and management.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV076

21 January 2018

Identifiers

10.1093/JAC/DKV076

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41378759&oldid=2096749713"